4.7 Review

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?

期刊

出版社

MDPI
DOI: 10.3390/ijms18061172

关键词

EZH2; cancer; epigenetic regulation; microRNAs; lncRNAs; EZH2 inhibitors

资金

  1. Wan Fang Hospital [105swf08]
  2. Ministry of Science and Technology [MOST 105-2320-B-039-059-MY3, MOST 105-2634-F-039-001]

向作者/读者索取更多资源

Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, catalyzes tri-methylation of histone H3 at Lys 27 (H3K27me3) to regulate gene expression through epigenetic machinery. EZH2 functions as a double-facet molecule in regulation of gene expression via repression or activation mechanisms, depending on the different cellular contexts. EZH2 interacts with both histone and non-histone proteins to modulate diverse physiological functions including cancer progression and malignancy. In this review article, we focused on the updated information regarding microRNAs (miRNAs) and long non coding RNAs (lncRNAs) in regulation of EZH2, the oncogenic and tumor suppressive roles of EZH2 in cancer progression and malignancy, as well as current pre-clinical and clinical trials of EZH2 inhibitors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据